January 28, 2025

New Member: Welcome in our cluster to Akribion Therapeutics GmbH

New Member: Welcome in our cluster to Akribion Therapeutics GmbH
Go back

Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence. This ensures that only the targeted cells are affected, leaving healthy cells unharmed.
Akribion is exploring applications in oncology, autoimmune diseases, fibrosis, and infectious diseases, as the technology can be quickly adapted to target different biomarkers and cells.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
Diaper Recycling: Progress Even Among the Market Leader

Diaper Recycling: Progress Even Among the Market Leader

Used diapers account for a very large portion of our waste, and to date, no economically viable recycling process has been established. In the Encycling project, the NMI team led by Dr. Anne Zeck and Dr. Simon Straß developed an enzymatic process that was successfully applied to diapers from various manufacturers. Further research was needed […]

read more
From microscopy to AI: Andreas von Deimling shaped modern brain tumor diagnostics in Heidelberg

From microscopy to AI: Andreas von Deimling shaped modern brain tumor diagnostics in Heidelberg

After almost 20 years, Professor Dr. Andreas von Deimling has handed over leadership of Neuropathology at Heidelberg University Hospital to Professor Dr. Dr. Felix Sahm. When Andreas von Deimling was appointed W3 Professor of Neuropathology in 2007, Heidelberg Faculty of Medicine at Heidelberg University, together with the German Cancer Research Center (DKFZ), pursued a strategic […]

read more
Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany. The new facility will bring a new generation of insulin production to one of Sanofi’s largest integrated research and manufacturing sites, […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp